Suppr超能文献

阐明不同蛋白酶体亚型的催化亚基组成:一种采用基于双功能活性探针的交联方法。

Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.

作者信息

Cornish Carmony Kimberly, Sharma Lalit Kumar, Lee Do-Min, Park Ji Eun, Lee Wooin, Kim Kyung-Bo

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596 (USA).

出版信息

Chembiochem. 2015 Jan 19;16(2):284-92. doi: 10.1002/cbic.201402491. Epub 2014 Dec 4.

Abstract

In addition to two well-recognized proteasome subtypes-constitutive proteasomes and immunoproteasomes-mounting evidence also suggests the existence of intermediate proteasome subtypes containing unconventional mixtures of catalytic subunits. Although they appear to play unique biological roles, the lack of practical methods for detecting distinct proteasome subtypes has limited functional investigations. Here, we report the development of activity-based probes that crosslink two catalytic subunits within intact proteasome complexes. Identification of the crosslinked subunit pairs provides direct evidence of the catalytic subunit composition of proteasomes. Using these probes, we found that U266 multiple myeloma cells contain intermediate proteasomes comprising both β1i and β2, but not β1 and β2i, consistent with previous findings with other cell types. Our bifunctional probes can be utilized in functional investigations of distinct proteasome subtypes in various biological settings.

摘要

除了两种广为人知的蛋白酶体亚型——组成型蛋白酶体和免疫蛋白酶体——越来越多的证据还表明存在含有催化亚基非常规混合物的中间蛋白酶体亚型。尽管它们似乎发挥着独特的生物学作用,但缺乏检测不同蛋白酶体亚型的实用方法限制了功能研究。在此,我们报告了基于活性的探针的开发,该探针可在完整的蛋白酶体复合物内交联两个催化亚基。交联亚基对的鉴定为蛋白酶体的催化亚基组成提供了直接证据。使用这些探针,我们发现U266多发性骨髓瘤细胞含有同时包含β1i和β2但不包含β1和β2i的中间蛋白酶体,这与之前在其他细胞类型中的发现一致。我们的双功能探针可用于各种生物学环境中不同蛋白酶体亚型的功能研究。

相似文献

2
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
Angew Chem Int Ed Engl. 2016 Mar 18;55(13):4199-203. doi: 10.1002/anie.201509092. Epub 2015 Oct 29.
3
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
J Med Chem. 2014 Jul 24;57(14):6197-209. doi: 10.1021/jm500716s. Epub 2014 Jul 15.
6
A FRET-based approach for identification of proteasome catalytic subunit composition.
Mol Biosyst. 2014 Feb;10(2):196-200. doi: 10.1039/c3mb70471h.
7
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Cancer Res. 2005 Sep 1;65(17):7896-901. doi: 10.1158/0008-5472.CAN-05-0506.
8
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. doi: 10.1073/pnas.1009778107. Epub 2010 Oct 11.
9
Two-Step Bioorthogonal Activity-Based Protein Profiling of Individual Human Proteasome Catalytic Sites.
Chembiochem. 2020 Jan 15;21(1-2):248-255. doi: 10.1002/cbic.201900551. Epub 2019 Nov 8.
10
Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Chembiochem. 2020 Nov 16;21(22):3220-3224. doi: 10.1002/cbic.202000375. Epub 2020 Jul 29.

引用本文的文献

1
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
Cancer Drug Resist. 2021;4(3):634-645. doi: 10.20517/cdr.2021.27. Epub 2021 May 30.

本文引用的文献

2
A FRET-based approach for identification of proteasome catalytic subunit composition.
Mol Biosyst. 2014 Feb;10(2):196-200. doi: 10.1039/c3mb70471h.
3
Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.
J Zhejiang Univ Sci B. 2013 Sep;14(9):816-28. doi: 10.1631/jzus.B1200299.
4
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Clin Cancer Res. 2013 Sep 1;19(17):4559-63. doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17.
5
Mixed proteasomes function to increase viral peptide diversity and broaden antiviral CD8+ T cell responses.
J Immunol. 2013 Jul 1;191(1):52-9. doi: 10.4049/jimmunol.1300802. Epub 2013 May 24.
6
Activity-based imaging probes of the proteasome.
Cell Biochem Biophys. 2013 Sep;67(1):91-101. doi: 10.1007/s12013-013-9626-4.
7
Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities.
Age (Dordr). 2014 Feb;36(1):57-72. doi: 10.1007/s11357-013-9543-x. Epub 2013 May 22.
10
Inhibitors of the immunoproteasome: current status and future directions.
Curr Pharm Des. 2013;19(22):4140-51. doi: 10.2174/1381612811319220018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验